The Chinese regime recently mandated that 50 million doses of COVID-19 vaccines must be administered to people designated as high risk by Feb. 15, 2021—although drug companies have yet to complete testing and the vaccines have yet to be approved by regulators.
Meanwhile, Fosun Pharmaceutical announced that it had ordered 100 million doses of the COVID-19 vaccine developed by German drug company BioNTech, which will arrive in China in 2021. BioNTech has partnered with Pfizer to supply vaccines for the U.S. and EU markets, which were approved by their respective regulators, but the vaccine developed for the China market is still in Phase II trial.
China has five different COVID-19 vaccines under development, according to health authorities.
Currently, all five are still under phase III trial, which is a clinical trial conducted on a large group of people to see whether the drug is efficient or has side effects.
Two of them…
Read the full story here: Beijing Mandates Millions Must Get China-Made COVID-19 Vaccine as Testing Continues